You are here: Home: CCU 4 | 2003: Robert B Diasio, MD: Select publications

Select publications

Publications discussed by Dr Diasio

Andre T et al. FOLFOX7 compared to FOLFOX4. Preliminary results of the randomized optimox study. Proc ASCO 2002; Abstract 1016.

Cunnigham D et al. Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC). Proc ASCO 2003;Abstract 1012.

de Gramont A et al. Oxaliplatin/5-FU/LV in adjuvant colon cancer: Results of the international randomized MOSAIC trial. Proc ASCO 2003;Abstract 1015.

de Gramont A et al. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: A French Intergroup study. J Clin Oncol 1997;15(2):808-15. Abstract.

Gamelin E et al. Prevention of oxaliplatin peripheral sensory neuropathy by Ca+ gluconate/ Mg+ chloride infusions: A retrospective study. Proc ASCO 2002;Abstract 624.

Garay CA et al. Randomized trial of bolus plus infusional 5-FU/leucovorin (LV5FU2) with/without oxaliplatin (FOLFOX4) after sequential fluoropyrimidine and CPT-11 in the treatment of advanced colorectal cancer (ACRC). Proc ASCO 2003;Abstract 1019.

Goldberg RM et al. N9741: Oxaliplatin (Oxal) or CPT-11 + 5-fluorouracil (5FU)/leucovorin (LV) or oxal + CPT-11 in advanced colorectal cancer (CRC). Updated efficacy and quality of life (QOL) data from an Intergroup study. Proc ASCO 2003;Abstract 1009.

Hurwitz H et al. Bevacizumab (a monoclonal antibody to vascular endothelial growth factor) prolongs survival in first-line colorectal cancer (CRC): Results of a phase III trial of bevacizumab in combination with bolus IFL (irinotecan, 5-fluorouracil, leucovorin) as first-line therapy in subjects with metastatic CRC. Proc ASCO 2003;Abstract 3646.

Rothenberg ML et al. Final results of a phase III trial of 5-FU/leucovorin versus oxaliplatin versus the combination in patients with metastatic colorectal cancer following irinotecan, 5-FU, and leucovorin. Proc ASCO 2003;Abstract 1011.

Smith RE et al. The occurrence of severe enteropathy among patients with stage II/III resected colon cancer (CC) treated with 5-FU/leucovorin (FL) plus oxaliplatin (FLOX). Proc ASCO 2003;Abstract 1181.

Van Cutsem E et al. XELOX: Mature results of a multinational, phase II trial of capecitabine plus oxaliplatin, an effective 1st line option for patients (pts) with metastatic colorectal cancer (MCRC). Proc ASCO 2003;Abstract 1023.